News und Analysen
EQS-News: Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
EQS-News: M1 Kliniken AG: Management Board confirms growth targets
Simulations Plus to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the
EQS-News: Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2024 financial results after the market close on Tuesday, July 2, 2024.
EGS Beteiligungen AG exercises right to convert bond and increases its shareholding in Siegfried to 6.2% registered shares
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the
Siegfried to acquire an early-phase CDMO in Wisconsin (US) to strengthen its Drug Substances service offering
EQS-News: M1 Kliniken announces change in the Management Board and confirms long-term growth strategy
EQS-News: MEDICLIN: Annual General Meeting of MEDICLIN AG approves all proposed resolutions
EQS-News: M1 Kliniken AG on a growth path with cutting-edge medicine: EBIT +70% in the first quarter of 2024
STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites
Inogen Announces Publication of Study Demonstrating the Association of Portable Oxygen Therapy with Decreased Mortality and Increased Cost-Effectiveness Ratio
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today shared the results of a study published in the journal
EQS-News: Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA
EQS-News: Vita 34 significantly increases earnings and operating cash flow in the first quarter
Owens & Minor to Present at the Leerink Partners’ Healthcare Crossroads Conference on May 29, 2024
Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution
EQS-News: MeVis publishes figures for the first half of fiscal year 2023/2024
EQS-News: Eckert & Ziegler receives “Best Managed Companies Award”
EQS-News: M1 Kliniken AG: Strong profit growth in 2023 underlines ambitious plans for global market leadership in medical aesthetics
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the
EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
Owens & Minor to Present at the BofA Securities 2024 Health Care Conference on May 15, 2024
Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution
Inogen Announces First Quarter 2024 Financial Results
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31